AccessibilityHelp
Q32 Bio logo

Q32 Bio(NASDAQ) QTTB

Market Cap$258.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-48%
5 Year-92%
1 Year+192%
1 Month-17%
Premium Feature
Moneyball Superscore
60/100
$8.82
+1.73%
+0.15Today
After hours$8.83+$0.01 (+0.11%)
Q32 Bio last closing stock price
MetricPriceDate
Last closeUSD 8.672026-10-21
Q32 Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.24%USD 8.012026-10-14
1 month-17.19%USD 10.472026-09-21
3 month-43.63%USD 15.382026-07-23
Year to date+161.14%USD 3.322025-12-31
1 year+191.92%USD 2.972025-10-21
3 year-53.24%USD 18.542023-10-20
5 year-91.97%USD 108.002021-10-22
Since inception-47.93%USD 16.652024-03-26

Q32 Bio Financials at a Glance

Market Cap

$258.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$53.74M

Net Income (TTM)

$33.79M

EPS (TTM)

$3.00

P/E Ratio

2.89

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$8.82

Volume

363,639.427

Open

$8.67

Previous Close

$8.80

Daily Range

$8.60 - $9.01

52-Week Range

$1.91 - $23.57

Estimated Earnings Date

Nov 12, 2026

QTTB News

Medical researchers - GettyImages-1096502340

Why Q32 Bio Stock Skyrocketed Today

Joe TenebrusoJul 13, 2026
Foolcom-Featured.png

Q32 Bio (QTTB) Q2 Loss Drops 45%

Motley Fool Markets TeamAug 6, 2025

QTTB: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Q32 Bio

Q32 Bio Inc. NASDAQ:QTTB develops treatments for autoimmune diseases. These medicines help patients with hair loss and skin inflammation. The company works to fix unbalanced immune responses.

Medications in the Pipeline

  • Bempikibart: Human antibody that blocks proteins triggering immune attacks; used to treat alopecia areata, an autoimmune condition that causes hair loss.
  • ADX-914-XL: Long-acting version of bempikibart in early stages; designed to provide medical activity with fewer doses for patients.
  • Complement Platform: Specialized technology for creating drugs that stop tissue damage; includes early-stage candidates for eye and kidney diseases.

Strategic Shifts and Funding

  • Sold ADX-097 assets to Akebia Therapeutics in Nov. 2025 for $10 million in initial payments and potential future milestones.
  • Regained full development and commercial rights to bempikibart from Amgen in Nov. 2023 following a partnership termination.
  • Raised $187.6 million in net proceeds through a public stock offering in July 2026.
  • Completed a private stock placement in May 2026 that generated $53.4 million in net proceeds.

Unique Scientific Approach

The company focuses on a specific immune pathway called IL-7R alpha to treat several inflammatory diseases. This tissue-targeted approach aims to stop immune attacks in specific organs while minimizing effects on the rest of the body.

Recent Financial Performance

  • Cash and cash equivalents totaled $106.3 million as of June 30, 2026.
  • Net loss was $16.6 million for the six-month period ended June 30, 2026.
  • Research and development expenses decreased $4.8 million year over year for the first half of 2026.
  • Market capitalization was $206.4 million with a price-to-earnings ratio of -7.6 in Q2 2026.

The Bottom Line

Q32 Bio has narrowed its focus to advancing its lead drug candidate for autoimmune hair loss through registration-directed trials. Strategic asset sales and recent large-scale financing rounds have strengthened its balance sheet to support late-stage clinical development.

AI Generated • Aug 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

24

CEO

Jodie P. Morrison

Website

www.q32bio.com

Headquarters

Waltham, MA 02451, US

QTTB Financials

Key Financial Metrics (TTM)

Gross Margin

99.84%

Operating Margin

39.94%

Net Income Margin

62.87%

Return on Equity

76.88%

Return on Capital

29.47%

Return on Assets

29.16%

Earnings Yield

34.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$258.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

29.77M

Volume

363.64K

Avg. Volume

715.02K

Financials (TTM)

Gross Profit

$53.65M

Operating Income

$21.46M

EBITDA

$34.53M

Operating Cash Flow

-$19.83M

Capital Expenditure

$0.00

Free Cash Flow

-$19.83M

Cash & ST Invst.

$106.27M

Total Debt

$5.30M

Q32 Bio Performance Analysis

Q32 Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,208,000-90.6%
20232023-12-31USD -6,651,000N/A
20242024-12-31USD 0N/A
20252025-12-31USD 53,737,000N/A
Q32 Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-100.0%
Q22026-06-30N/A
Q32 Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.57-95.0%
20232023-12-31USD -153.979709.3%
20242024-12-31USD -6.58-95.7%
20252025-12-31USD 2.42N/A
Q32 Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3023.1%
Q42025-12-31828.3%
Q12026-03-31-112.4%
Q22026-06-3018.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$85.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$258.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.73M

N/A

Employees

22

N/A

Net Income

-$8.95M

+5.7%

EBITDA

-$8.86M

+2.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$106.27M

+93.8%

Total Debt

$5.30M

-71.7%

Accounts Receivable

$2.39M

+331.0%

Inventory

$0.00

N/A

Long Term Debt

$9.12M

-22.8%

Short Term Debt

$735.00K

-89.3%

Return on Assets

29.16%

N/A

Return on Invested Capital

19.43%

N/A

Free Cash Flow

-$3.08M

+71.1%

Operating Cash Flow

-$3.08M

+71.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SABSSAB Biotherapeutics, Inc.
$3.04+7.80%
ANTXAN2 Therapeutics, Inc.
$3.64+1.11%
VRCAVerrica Pharmaceuticals Inc.
$3.83+5.51%
BOLDBoundless Bio, Inc.
$2.44+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$7.88-14.81%
SPCXSpace Exploration Technologies
$144.75-9.14%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$82.11-20.47%
INTCIntel
$85.49-8.04%

Questions About QTTB

What is the current price of Q32 Bio?

Q32 Bio is trading at $8.80 per share.

What is the 52-week range for Q32 Bio?

Over the past 52 weeks, Q32 Bio has traded between $1.91 and $23.57.

How much debt does Q32 Bio have?

As of the most recent reporting period, Q32 Bio reported total debt of $5.30M.

How much cash does Q32 Bio have on hand?

Q32 Bio reported $106.27M in cash and cash equivalents in its most recent financial results.

What is Q32 Bio’s dividend yield?

Q32 Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services